The National Institute on Aging, a division of the National Institutes of Health, is awarding a $1.76 million, one-year grant to support a Phase 1 clinical trial investigating oral Jotrol as a potential treatment of early stage Alzheimer’s disease. The study is to be called “Safety and Pharmacokinetics of JOTROL for Alzheimer’s Disease.” Further information, including an anticipated launch date, was not available in a press release. Jotrol, made by Jupiter Orphan Therapeutics, is a more biologically active…
You must be logged in to read/download the full post.
The post $1.76M Grant to Support Trial of Jotrol, Form of Resveratrol, in Early Alzheimer’s appeared first on BioNewsFeeds.